Navigation Links
The fight against uterine fibroid tumors

CHICAGO ---As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

"Uterine fibroids represent the most prevalent benign gynecologic problem in our nation. This is truly an understudied area and a serious public health problem," said Serdar E. Bulun, M.D., George H. Gardner professor of clinical gynecology and chief of the division of reproductive biology research at Northwestern University Feinberg School of Medicine, who also is a physician at Northwestern Memorial Hospital.

Thanks to $5.7 million in funding from the Eunice Kennedy Shriver National Institute of Child Health and Development, part of the National Institutes of Health, Bulun and researchers at the Uterine Leiomyoma Research Center at Feinberg have the funding they need to continue investigating new treatments of uterine fibroids.

Principal investigator of the center grant, Bulun is studying the cause of this chronic problem, as well as treatment options such as investigating hormonal pathways and defining molecular targets for existing or upcoming pharmaceutical compounds developing novel and alternative management options.

Bulun's research suggests that the hormone progesterone, which enables and activates fibroid growth during childbearing years, stimulates uterine fibroids. His recent work uncovered the mechanism as to how a class of drugs called selective progesterone receptor modulators reduces fibroid size and associated symptoms. The mechanisms regulating the development and growth of these tumors are still not well understood, however, so treatment options for fibroids are limited.

Besides Bulun, Julie Kim, Debu Chakravarti, Takeshi Kurita, and Erica Marsh, M.D., from Feinberg and Romana Nowak, from University of Illinois at Urbana-Champaign, lead key projects at the Uterine Leiomyoma Research Center.

Uterine fibroids are typically treated surgically, through a myomectomy or hysterectomy, or using newer technologies involving interventional radiology or high-intensity ultrasound. GnRH agonists, developed in the 1980s, are the only class of drugs available to treat fibroids, but their success is extremely limited, and side effects prevent long-term use of the medication.

The renewable five-year P01 Program Project offers Bulun and his colleagues the opportunity to find answers to these uncertainties and diminish the suffering caused by uterine fibroids.

"This center is a unique entity," Bulun said. "We approach the translational aspects of uterine fibroids in a multidisciplinary manner. We hope our research will encourage the pharmaceutical industry and clinicians to set up clinical trials."


Contact: Erin White
Northwestern University

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Social habits of cells may hold key to fighting diseases
3. Advance in effort to fight malaria by tricking the mosquitos sense of smell
4. Yale scientists use nanotechnology to fight E. coli
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Japanese beetle may help fight hemlock-killing insect
7. When it comes fighting to C. difficile, the Palme dOr goes to soap and warm water
8. Fighting the spread of food poisoning
9. Gold nanorods shed light on new approach to fighting cancer
10. UMass Medical School researchers receive $8.5M grant award to fight AIDS
11. UV light improving chances of fighting cancer
Post Your Comments:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with ... and other AMA team leaders met with OPBAP leaders Capt. Karl Minter and ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology: